Popular Peptide, Divided Regulatory Vote

BPC-157 has become widely promoted for recovery, tissue healing, gastrointestinal conditions and longevity. Yet it is not an FDA-approved drug, and many of the claims circulating online extend well beyond the available human evidence.

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend that BPC-157-related substances be included on the Section 503A Bulks List. Inclusion would create a pathway for eligible patient-specific pharmacy compounding under defined legal conditions. It would not constitute FDA approval or validation of the peptide’s marketed benefits.

The divided vote also ran against FDA staff’s assessment. The agency concluded that BPC-157 and BPC-157 acetate were not adequately characterized, that evidence was insufficient to establish effectiveness for the evaluated indication of ulcerative colitis, and that available clinical safety information could not define a reliable safety profile. FDA also identified possible immunogenicity risks related to impurities and peptide aggregation.

Advisory committee recommendations are non-binding. FDA must still complete its review and determine whether to add the substances to the 503A Bulks List.